Technology NetworksCRISPR Enhances Cancer Immunotherapy Helping Protect T-Cells Against Friendly FireTechnology NetworksScientists at Washington University School of Medicine in St. Louis now have used the gene-editing technology CRISPR to engineer hum… Continue reading
Drug Target ReviewPreventing exhaustion in immune cells boosts immunotherapy in miceDrug Target ReviewNew research from the University of Pittsburgh School of Medicine and the UPMC Hillman Cancer Center shows that preventing or reversing this metabolic… Continue reading
Preventing metabolic exhaustion in immune cells could enhance effects of immunotherapyBrinkwire (press release)Cancer immunotherapies that improve the ability of T-cells – highly specialized immune soldiers – to attack cancer have made major strides in… Continue reading
Synthetic Biology Market 2018 : Global Market Synopsis, Growth Factors, Industry Segmentation, Regional Analysis …Pharmaceuticals NewsIn-Depth research analysis of the Research industry. Research on the different Market size, Trends and the emerging … Continue reading
Pig Progress (blog)Can gene editing solve the castration issue?Pig Progress (blog)Until recently, DNA editing had been a relatively inexact process. CRISPR was presented as a way to change a single letter in the DNA through an enzyme that cuts DNA, cop… Continue reading
ReuropeEditas Medicine Announces Fourth Quarter and Full Year 2017 Results and UpdateMarkets InsiderAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing… Continue reading
San Francisco Chronicle |
Tiny biotech takes on Glaxo’s $730000 gene therapy
San Francisco Chronicle Orchard, whose team includes three former Glaxo executives, wants to one-up the larger company by taking aim at a Strimvelis shortcoming. While Glaxo’s therapy can’t be transported, Orchard is planning to use frozen cells that can travel to markets all … |
|
Tiny biotech takes on Glaxo’s $730000 gene therapy
SFGate GlaxoSmithKline has seen precious few takers for its $730,000 gene therapy for a rare and life-threatening immune illness known as “bubble-boy disease.” Now a tiny startup thinks it can succeed where the British giant is struggling. In almost two years … |